Orexigen Therapeutics (OREX) Reports Q2 Loss of $2.00/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. AMD
3. PLTR
4. CRWD
5. DOX
6. VRTX
7. CHKP
8. ON
9. HNGE
10. INSP

Go back to Orexigen Therapeutics (OREX) Reports Q2 Loss of $2.00/Share

Orexigen Therapeutics Announces Second Quarter 2017 Financial Results

August 8, 2017 4:01 PM EDT

SAN DIEGO, Aug. 8, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the second quarter ended June 30, 2017.

"Our performance in the second quarter of 2017 reflects the successful implementation of our commercial strategy that we launched late last year.  The team at Orexigen has delivered dramatic growth of U.S. Contrave sales in the first half of 2017," said Mike Narachi, President and Chief Executive Officer of Orexigen.  He continued, "In addition to delivering strong growth from an innovative and highly-efficient primary care model, we have... More